EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Artificial intelligence in inflammatory bowel disease: implications for clinical practice and future directions

Harris A Ahmad, James E East, Remo Panaccione, Simon Travis, James B Canavan, Keith Usiskin, Michael F Byrne

Intestinal Research · 31.07.2023 · 21 (3) · 283-294

DOI: 10.5217/ir.2023.00020 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Intestinal Research, erschienen am 31.07.2023. Verfasst von Harris A Ahmad und 6 weiteren Autor:innen. Beteiligte Einrichtung: Bristol Myers Squibb, Princeton, NJ, USA. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inflammatory bowel disease encompasses Crohn’s disease and ulcerative colitis and is characterized by uncontrolled, relapsing, and remitting course of inflammation in the gastrointestinal tract. Artificial intelligence represents a new era within the field of gastroenterology, and the amount of research surrounding artificial intelligence in patients with inflammatory bowel disease is on the rise. As clinical trial outcomes and treatment targets evolve in inflammatory bowel disease, artificial intelligence may prove as a valuable tool for providing accurate, consistent, and reproducible evaluations of endoscopic appearance and histologic activity, thereby optimizing the diagnosis process and identifying disease severity. Furthermore, as the applications of artificial intelligence for inflammatory bowel disease continue to expand, they may present an ideal opportunity for improving disease management by predicting treatment response to biologic therapies and for refining the standard of care by setting the basis for future treatment personalization and cost reduction. The purpose of this review is to provide an overview of the unmet needs in the management of inflammatory bowel disease in clinical practice and how artificial intelligence tools can address these gaps to transform patient care.

Schlagwörter

Stichwörter der Autor:innen

Artificial intelligenceEndoscopyInflammatory bowel diseases

Autor:innen und Institutionen

  • Bristol Myers Squibb, Princeton, NJ, USA.
  • Translational Gastroenterology Unit, Oxford NIHR Biomedical Research Centre, University of Oxford, Oxford, UK.
  • Inflammatory Bowel Disease Clinic, University of Calgary, Calgary, AB, Canada.
  • Division of Gastroenterology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada.
  • Satisfai Health, Vancouver, BC, Canada.

Zitieren

APA

Ahmad, H. A., East, J. E., Panaccione, R., Travis, S., Canavan, J. B., Usiskin, K., & Byrne, M. F. (2023). Artificial intelligence in inflammatory bowel disease: implications for clinical practice and future directions. Intestinal Research, 21(3), 283-294. https://doi.org/10.5217/ir.2023.00020

Vancouver

Ahmad HA, East JE, Panaccione R, Travis S, Canavan JB, Usiskin K, et al. Artificial intelligence in inflammatory bowel disease: implications for clinical practice and future directions. Intestinal Research. 2023;21(3):283-294. doi:10.5217/ir.2023.00020

BibTeX
@article{Ahmad2023,
  author = {Ahmad, Harris A and East, James E and Panaccione, Remo and Travis, Simon and Canavan, James B and Usiskin, Keith and Byrne, Michael F},
  title = {Artificial intelligence in inflammatory bowel disease: implications for clinical practice and future directions},
  journal = {Intestinal Research},
  year = {2023},
  volume = {21},
  number = {3},
  pages = {283--294},
  doi = {10.5217/ir.2023.00020}
}
Kostenlos starten →